Baxdrostat Drug Asset Due Diligence Report 2026

This Baxdrostat Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Baxdrostat can convert its Small molecule drug profile and CYP11B2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Baxdrostat (query alias: baxdrostat)
Modality / target	Small molecule drug; CYP11B2; CYP11B2 inhibitors
Highest global status	Approved
Originator	CinCor Pharma, Inc.
Active developers	AstraZeneca PLC, AstraZeneca Global R&D (China) Co., Ltd., AstraZeneca AB

The MCP disease footprint includes Hypertension, Resistant hypertension, Hyperaldosteronism. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07686120	Phase 3	Not yet recruiting	286	Change from baseline in ambulatory 24-hour average Systolic blood pressure(SBP) at Week 12
NCT07655362	Phase 3	Not yet recruiting	286	Left Ventricular Mass indexed to baseline body surface area (LVMi)
NCT07007793	Phase 3	Recruiting	250	Change from baseline in seated Systolic Blood Pressure (SBP) at Week 8

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Effectiveness of CIN-107 for the Management of Blood Pressure in Patients With Primary Aldosteronism

Phase 2; n=15; evaluation: not stated. Reported fields: -; -; Part 1 before titration (0-Week 4) = 27 Number of events

Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial

Phase 3; n=217; evaluation: Positive. Reported fields: AE = 37.0 % ; AE = 52.0 %

A Randomised, Double-blind, Placebo-controlled Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone Stimulation Test Following Treatment With Baxdrostat for 8 Weeks in Participants With Uncontrolled Hypertension

Phase 2; n=48; evaluation: not stated. Reported fields: Abnormal Stimulated cortisol at Week 8 = 0 Participants ; Abnormal Stimulated cortisol at Week 8 = 0 Participants ; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Baxdrostat addresses Hypertension, Resistant hypertension, Hyperaldosteronism. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2023-01-09	AstraZeneca complete Acquisition of CinCor Pharma	Phase 2	US$1,300.0M upfront; US$1,800.0M stated total
2019-05-14	CinCor Pharma In-Licenses Aldosterone Synthase Inhibitor, CIN-107, from Roche, and Closes $50 Million Series A Financing	Phase 1	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Crystal form of baxdrostat, and preparation method therefor and use thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO